Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
UCB S.A. (UCB.BR)
Brussels, BE
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.07% | +3.88% | +8.87% | -0.24% | +4.66% | +5.49% | +55.37% | +208.76% | +228.93% | +287.53% | +513.90% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 13 | 0 |
| Hold | 3 | -1 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Biotechnology: +1.6%+25.8% ★ Q4'25: +59.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+50.2% ★ Q4'25: +3,462.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+20.9% Q4'25: +32.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+26.0% ★ Q4'25: +30.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+16.1% ★ Q4'25: +42.7% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-2.6% ★ Q4'25: -4.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.12× ★ Q4'25: 0.44× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 14 EPS Ana. |
Dec 2027 16 Rev. Ana. 14 EPS Ana. |
Dec 2028 15 Rev. Ana. 10 EPS Ana. |
Dec 2029 11 Rev. Ana. 4 EPS Ana. |
Dec 2030 7 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.62B
est.
|
5.64B
est: 2.56B (+120.5%)
|
3.33B
est: 3.12B (+6.8%)
|
3.53B
est: 3.23B (+9.5%)
|
2.34B
est: 2.20B (+6.4%)
|
2.52B
est: 2.42B (+4.3%)
|
3.63B
est: 3.52B (+2.9%)
|
3.60B
est: 3.27B (+10.0%)
|
3.12B
est: 3.09B (+0.8%)
|
3.22B
est: 3.09B (+4.0%)
|
3.25B
est: 3.15B (+3.1%)
|
3.46B
est: 3.26B (+6.1%)
|
3.13B
est: 3.44B (-8.9%)
|
3.34B
est: 3.39B (-1.5%)
|
3.88B
est: 3.73B (+3.9%)
|
4.15B
est: 4.13B (+0.4%)
|
4.47B
est: 4.44B (+0.7%)
|
4.63B
est: 4.58B (+1.1%)
|
4.91B
est: 4.83B (+1.6%)
|
5.35B
est: 5.16B (+3.7%)
|
5.78B
est: 5.61B (+3.0%)
|
5.52B
est: 5.32B (+3.7%)
|
5.25B
est: 5.45B (-3.7%)
|
6.15B
est: 5.83B (+5.5%)
|
7.74B
est: 7.60B (+1.8%)
|
8.50B
8.17B – 8.77B
+11.7% YoY
|
9.59B
9.09B – 9.97B
+12.9% YoY
|
10.78B
10.75B – 10.81B
+12.4% YoY
|
11.93B
11.39B – 12.37B
+10.7% YoY
|
12.92B
12.33B – 13.39B
+8.3% YoY
|
| EBITDA |
749.75M
est.
|
829.75M
est: 751.53M (+10.4%)
|
797.61M
est: 1.07B (-25.2%)
|
355.00M
est: 978.20M (-63.7%)
|
503.00M
est: 643.73M (-21.9%)
|
678.00M
est: 1.04B (-34.6%)
|
545.00M
est: 811.30M (-32.8%)
|
270.00M
est: 238.81M (+13.1%)
|
1.00B
est: 81.89M (+1,122.4%)
|
430.00M
est: 823.61M (-47.8%)
|
610.00M
est: 128.22M (+375.8%)
|
637.00M
est: 465.44M (+36.9%)
|
544.00M
est: 394.37M (+37.9%)
|
600.00M
est: 415.19M (+44.5%)
|
829.00M
est: 367.84M (+125.4%)
|
1.09B
est: 1.01B (+7.4%)
|
1.27B
est: 938.13M (+35.5%)
|
1.40B
est: 1.16B (+20.4%)
|
1.33B
est: 1.26B (+5.9%)
|
1.30B
est: 1.25B (+4.2%)
|
1.59B
est: 1.32B (+20.6%)
|
1.17B
est: 1.35B (-13.5%)
|
1.28B
est: 1.43B (-10.6%)
|
1.96B
est: 1.54B (+27.5%)
|
2.01B
est: 1.99B (+0.9%)
|
2.22B
2.14B – 2.30B
+11.7% YoY
|
2.51B
2.38B – 2.61B
+12.9% YoY
|
2.82B
2.81B – 2.83B
+12.4% YoY
|
3.12B
2.98B – 3.24B
+10.7% YoY
|
3.38B
3.23B – 3.50B
+8.3% YoY
|
| EBIT |
447.70M
est.
|
502.40M
est: 452.51M (+11.0%)
|
486.54M
est: 578.76M (-15.9%)
|
281.00M
est: 489.61M (-42.6%)
|
410.00M
est: 341.89M (+19.9%)
|
588.00M
est: 396.07M (+48.5%)
|
385.00M
est: 831.69M (-53.7%)
|
141.00M
est: 319.65M (-55.9%)
|
896.00M
est: 106.08M (+744.6%)
|
213.00M
est: 837.63M (-74.6%)
|
368.00M
est: 207.59M (+77.3%)
|
407.00M
est: 356.59M (+14.1%)
|
278.00M
est: 386.99M (-28.2%)
|
380.00M
est: 394.48M (-3.7%)
|
577.00M
est: 289.82M (+99.1%)
|
851.00M
est: 577.97M (+47.2%)
|
1.08B
est: 916.69M (+17.3%)
|
1.08B
est: 1.13B (-4.5%)
|
1.02B
est: 1.16B (-12.1%)
|
948.00M
est: 1.16B (-18.4%)
|
1.27B
est: 1.23B (+3.4%)
|
582.00M
est: 1.26B (-53.7%)
|
585.00M
est: 994.05M (-41.1%)
|
1.32B
est: 1.07B (+23.3%)
|
2.01B
est: 1.39B (+44.9%)
|
1.55B
1.49B – 1.60B
+11.7% YoY
|
1.75B
1.66B – 1.82B
+12.9% YoY
|
1.96B
1.96B – 1.97B
+12.4% YoY
|
2.17B
2.08B – 2.25B
+10.7% YoY
|
2.35B
2.25B – 2.44B
+8.3% YoY
|
| Net Income |
313.27M
est.
|
331.81M
est: 313.67M (+5.8%)
|
339.68M
est: 404.68M (-16.1%)
|
363.04M
est: 342.73M (+5.9%)
|
755.00M
est: 245.98M (+206.9%)
|
367.00M
est: 829.54M (-55.8%)
|
161.00M
est: 534.56M (-69.9%)
|
43.00M
est: 148.67M (-71.1%)
|
514.00M
est: 39.08M (+1,215.2%)
|
104.00M
est: 513.38M (-79.7%)
|
235.00M
est: 104.81M (+124.2%)
|
256.00M
est: 243.60M (+5.1%)
|
82.00M
est: 269.94M (-69.6%)
|
115.00M
est: 204.14M (-43.7%)
|
264.00M
est: 232.97M (+13.3%)
|
520.00M
est: 689.80M (-24.6%)
|
753.00M
est: 557.52M (+35.1%)
|
800.00M
est: 782.08M (+2.3%)
|
792.00M
est: 837.44M (-5.4%)
|
732.00M
est: 860.00M (-14.9%)
|
1.06B
est: 910.36M (+16.2%)
|
418.00M
est: 332.00M (+25.9%)
|
343.00M
est: 240.00M (+42.9%)
|
1.07B
est: 843.92M (+26.2%)
|
1.56B
est: 1.56B (+0.0%)
|
2.04B
1.90B – 2.18B
+30.9% YoY
|
2.70B
2.30B – 3.09B
+32.1% YoY
|
2.82B
2.59B – 3.94B
+4.6% YoY
|
3.96B
3.72B – 4.15B
+40.4% YoY
|
4.57B
4.30B – 4.79B
+15.5% YoY
|
| SGA |
1.40B
est.
|
604.13M
est: 1.35B (-55.3%)
|
712.31M
est: 1.71B (-58.2%)
|
736.63M
est: 1.57B (-53.0%)
|
883.00M
est: 1.18B (-25.0%)
|
929.00M
est: 928.56M (+0.0%)
|
1.32B
est: 1.35B (-2.4%)
|
1.16B
est: 1.23B (-5.8%)
|
970.00M
est: 1.08B (-9.8%)
|
991.00M
est: 970.72M (+2.1%)
|
1.03B
est: 1.01B (+2.1%)
|
1.07B
est: 1.07B (+0.5%)
|
996.00M
est: 1.13B (-12.0%)
|
980.00M
est: 993.11M (-1.3%)
|
1.10B
est: 1.09B (+0.3%)
|
1.12B
est: 1.24B (-9.8%)
|
1.13B
est: 1.21B (-6.1%)
|
1.14B
est: 1.22B (-6.3%)
|
1.30B
est: 1.21B (+7.5%)
|
1.42B
est: 1.41B (+0.3%)
|
1.55B
est: 1.50B (+3.9%)
|
1.71B
est: 1.53B (+12.2%)
|
1.82B
est: 1.81B (+0.5%)
|
2.35B
est: 1.96B (+19.9%)
|
2.75B
est: 2.53B (+8.6%)
|
2.83B
2.72B – 2.92B
+11.7% YoY
|
3.19B
3.02B – 3.32B
+12.9% YoY
|
3.59B
3.58B – 3.60B
+12.4% YoY
|
3.97B
3.79B – 4.11B
+10.7% YoY
|
4.30B
4.10B – 4.45B
+8.3% YoY
|
| EPS |
2.18
est.
|
1.84
est: 2.37 (-22.2%)
|
2.33
est: 2.31 (+1.0%)
|
2.51
est: 2.46 (+2.0%)
|
5.26
est: 2.01 (+162.1%)
|
2.54
est: 2.05 (+24.1%)
|
0.89
est: 1.62 (-45.0%)
|
0.24
est: 1.62 (-85.2%)
|
2.85
est: 1.52 (+88.0%)
|
0.58
est: 1.65 (-64.8%)
|
1.23
est: 1.86 (-33.9%)
|
1.43
est: 1.76 (-18.6%)
|
0.45
est: 1.92 (-76.5%)
|
0.60
est: 1.73 (-65.3%)
|
1.37
est: 2.06 (-33.4%)
|
2.88
est: 3.01 (-4.3%)
|
3.99
est: 4.23 (-5.6%)
|
4.24
est: 4.56 (-6.9%)
|
4.23
est: 4.77 (-11.3%)
|
3.87
est: 4.86 (-20.4%)
|
5.60
est: 6.02 (-7.0%)
|
2.20
est: 4.07 (-46.0%)
|
1.81
est: 1.26 (+43.3%)
|
5.61
est: 4.47 (+25.5%)
|
8.20
est: 8.39 (-2.3%)
|
10.65
10.00 – 11.47
+26.9% YoY
|
13.75
12.09 – 16.28
+29.1% YoY
|
17.09
13.64 – 20.71
+24.3% YoY
|
20.84
19.60 – 21.82
+22.0% YoY
|
24.06
22.63 – 25.20
+15.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jean-Christophe Tellier | Chief Executive Officer & Executive Director | 6M | male |
| Emmanuel Caeymaex | Executive Vice President of Patient Evidence | 32.8K | male |
| Caroline Vancoillie | Chief Accounting Officer & Head of Group Finance | — | female |
| Denelle J. Waynick Johnson | Executive Vice President & General Counsel | — | female |
| Fiona du Monceau | Executive VP of Patient Impact & Chief Commercial Officer | — | female |
| Gwendoline Ornigg | Head of Global Corporate Communication | — | — |
| Jean-Luc Fleurial | Executive Vice President & Chief Human Resources Officer | — | male |
| Kirsten Lund-Jurgensen | Executive Vice President of Patient Supply | — | female |
| Alistair Henry | Executive Vice President & Chief Scientific Officer | — | male |
| Sandrine Dufour | Executive VP & CFO | — | female |
| Antje Witte | Head of Investor Relations | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for UCB.BR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
